Prab: CSV import

2025-03-07T01:47:33Z

CSV import

← Older revision		Revision as of 01:47, 7 March 2025
Line 9:		Line 9:
	}}		}}

	'''Selatogrel''' is a novel [[antiplatelet drug]] that acts as a ~~potent and selective~~ [[P2Y12 receptor]] antagonist. It is being developed for the treatment of [[acute coronary syndrome]] (ACS) and other conditions where inhibition of platelet aggregation is desired.		'''Selatogrel''' is a novel [[antiplatelet drug]] that acts as a [[P2Y12 receptor]] antagonist. It is being developed for the treatment of [[acute coronary syndrome]] (ACS) and other conditions where inhibition of platelet aggregation is desired.

	==Mechanism of Action==		==Mechanism of Action==
	Selatogrel works by inhibiting the P2Y12 receptor, a key receptor involved in the activation of [[platelets]]. ~~The P2Y12 receptor is a [[G protein-coupled~~ receptor~~]] that~~, ~~when activated by~~ [[adenosine diphosphate]] (ADP), ~~leads to~~ platelet ~~activation and aggregation. By blocking this receptor, selatogrel prevents ADP from binding~~, thereby reducing platelet aggregation and thrombus formation.		Selatogrel works by selectively inhibiting the [[P2Y12 receptor]], a key receptor involved in the activation of [[platelets]]. By blocking this receptor, selatogrel prevents the binding of [[adenosine diphosphate]] (ADP), a potent platelet activator, thereby reducing platelet aggregation and thrombus formation.

	==Pharmacokinetics==		==Pharmacokinetics==
	Selatogrel is administered via subcutaneous injection, which allows for rapid absorption and onset of action. The drug ~~has a high affinity for the P2Y12 receptor~~, ~~and its effects are dose-dependent. The pharmacokinetic profile of selatogrel supports its use~~ in acute ~~settings, such as during an episode~~ of ~~acute coronary syndrome, where rapid platelet inhibition is critical~~.		Selatogrel is administered via subcutaneous injection, which allows for rapid absorption and onset of action. The drug is designed to provide quick and effective platelet inhibition, which is crucial in the acute management of thrombotic events.

	==Clinical Development==		==Clinical Development==
	Selatogrel is currently undergoing clinical trials to evaluate its efficacy and safety in patients with acute coronary syndrome. ~~Early~~ studies have shown promising results, with rapid onset of action and significant inhibition of platelet aggregation~~. The drug is being compared to existing antiplatelet therapies to determine its potential advantages in terms of efficacy, safety, and patient outcomes~~.		Selatogrel is currently undergoing clinical trials to evaluate its efficacy and safety in patients with acute coronary syndrome. Preliminary studies have shown promising results, with rapid onset of action and significant inhibition of platelet aggregation.

	==Potential Benefits==		==Potential Benefits==
	The rapid ~~onset of~~ action ~~and potent inhibition~~ of ~~platelet aggregation make~~ selatogrel a ~~promising candidate for the treatment of acute coronary syndrome~~. Its subcutaneous route of administration offers a convenient alternative to oral antiplatelet agents, ~~particularly~~ in ~~emergency situations where immediate intervention is required~~.		The rapid action of selatogrel makes it a potentially valuable option in emergency settings where quick platelet inhibition is necessary. Its subcutaneous route of administration offers a convenient alternative to oral antiplatelet agents, especially in patients who are unable to take oral medications.

	==Side Effects==		==Side Effects==
	As with other antiplatelet ~~drugs~~, the primary side effect of selatogrel is an increased risk of bleeding. Other potential side effects include [[bruising]], [[nausea]], and [[headache]]~~. Ongoing clinical trials are assessing the safety profile of selatogrel in a larger patient population~~.		As with other antiplatelet agents, the primary side effect of selatogrel is an increased risk of bleeding. Other potential side effects include [[bruising]], [[nausea]], and [[headache]].

	==Related ~~Pages~~==		==Related pages==
	* [[Antiplatelet drug]]		* [[Antiplatelet drug]]
	* [[P2Y12 receptor]]		* [[P2Y12 receptor]]
	* [[Acute coronary syndrome]]		* [[Acute coronary syndrome]]
	* [[Platelet]]		* [[Platelet aggregation]]

	[[Category:Antiplatelet drugs]]		[[Category:Antiplatelet drugs]]
	[[Category:~~P2Y12 receptor antagonists~~]]		[[Category:Thiazoles]]
			[[Category:Piperazines]]

Prab: CSV import

2025-03-05T06:22:44Z

CSV import

New page

{{Short description|A novel antiplatelet drug}}
{{Drugbox
| verifiedfields = changed
| verifiedrevid = 477002123
| IUPAC_name = (2S)-2-[[4-[[3-(2-chlorophenyl)-1,2,4-oxadiazol-5-yl]methyl]piperazin-1-yl]methyl]-4-methyl-1,3-thiazole-5-carboxylic acid
| image = Selatogrel.svg
| image_size = 200px
| image_alt = Chemical structure of Selatogrel
}}

'''Selatogrel''' is a novel [[antiplatelet drug]] that acts as a potent and selective [[P2Y12 receptor]] antagonist. It is being developed for the treatment of [[acute coronary syndrome]] (ACS) and other conditions where inhibition of platelet aggregation is desired.

==Mechanism of Action==
Selatogrel works by inhibiting the P2Y12 receptor, a key receptor involved in the activation of [[platelets]]. The P2Y12 receptor is a [[G protein-coupled receptor]] that, when activated by [[adenosine diphosphate]] (ADP), leads to platelet activation and aggregation. By blocking this receptor, selatogrel prevents ADP from binding, thereby reducing platelet aggregation and thrombus formation.

==Pharmacokinetics==
Selatogrel is administered via subcutaneous injection, which allows for rapid absorption and onset of action. The drug has a high affinity for the P2Y12 receptor, and its effects are dose-dependent. The pharmacokinetic profile of selatogrel supports its use in acute settings, such as during an episode of acute coronary syndrome, where rapid platelet inhibition is critical.

==Clinical Development==
Selatogrel is currently undergoing clinical trials to evaluate its efficacy and safety in patients with acute coronary syndrome. Early studies have shown promising results, with rapid onset of action and significant inhibition of platelet aggregation. The drug is being compared to existing antiplatelet therapies to determine its potential advantages in terms of efficacy, safety, and patient outcomes.

==Potential Benefits==
The rapid onset of action and potent inhibition of platelet aggregation make selatogrel a promising candidate for the treatment of acute coronary syndrome. Its subcutaneous route of administration offers a convenient alternative to oral antiplatelet agents, particularly in emergency situations where immediate intervention is required.

==Side Effects==
As with other antiplatelet drugs, the primary side effect of selatogrel is an increased risk of bleeding. Other potential side effects include [[bruising]], [[nausea]], and [[headache]]. Ongoing clinical trials are assessing the safety profile of selatogrel in a larger patient population.

==Related Pages==
* [[Antiplatelet drug]]
* [[P2Y12 receptor]]
* [[Acute coronary syndrome]]
* [[Platelet]]

[[Category:Antiplatelet drugs]]
[[Category:P2Y12 receptor antagonists]]

Selatogrel - Revision history

Prab: CSV import

Prab: CSV import